Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent

Authors: Du, Rong-Hui1; Yi, Hong-Wei2; Dai, De-Zai3; Tang, Wei-Hua4; Dai, Yin5

Source: Journal of Pharmacy and Pharmacology, Volume 60, Number 8, August 2008 , pp. 1089-1095(7)

Publisher: Pharmaceutical Press

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The aim of this study was to verify whether exaggerated arrhythmogenesis is attributed to inflammatory factors actively involving an excess of reactive oxygen species (ROS), transforming growth factor (TGF)-β and endothelin (ET). We hypothesized that CPU86017, derived from berberine, which possesses multi-channel blocking activity, could suppress inflammatory factors, resulting in inhibition of over-expression of ether-a-go-go (ERG) and an augmented incidence of ventricular fibrillation (VF) in ischaemia/reperfusion (I/R). Rats with cardiomyopathy (CMP) induced by thyroxine (0.2 mg-1kg-1 s.c. daily for 10 days) were treated with propranolol (10 mgkg-1 p.o.) or CPU86017 (80 mgkg-1 p.o.) on days 6-10. On the 11th day, arrhythmogenesis of the CMP was evaluated by I/R. In the CMP control group, an increase in VF incidence was found with the I/R episode, accompanied by increased ROS, which manifested as an increased level of malondialdehyde and decreased activities of SOD, glutathione peroxidase and catalase in the myocardium. Levels of inducible nitric oxide synthase and TGF-β mRNA were increased in association with upregulation of preproET-1 and ET-converting enzyme. We found increased levels of ERG, which correlated well with arrhythmogenesis. Treatment with CPU86017 or propranolol reversed these changes. These experiments verified our hypothesis that the inflammatory factors ROS, iNOS, TGF-β and ET-1 are actively involved in upregulation of ERG and arrhythmogenesis. CPU86017 and propranolol reduced VF by suppressing these inflammatory factors in the myocardium.

Document Type: Review article

DOI: 10.1211/jpp.60.8.0015

Affiliations: 1: Medical college of Nanjing University, Nanjing, 210093, China; Research Division of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China 2: State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210093, China 3: Research Division of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China., Email: dezaidai@vip.sina.com 4: Medical college of Nanjing University, Nanjing, 210093, China 5: Research Division of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$38.49 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A